ELMUMY - HORIZON-MISS-2021-CANCER-02-03

ELMUMY aims at yielding clinically actionable molecular features that could improve MM patient management.

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

📄New publication from the NKUA team titled “𝐃𝐞𝐥𝐯𝐢𝐧𝐠 𝐢𝐧𝐭𝐨 𝐭𝐑𝐍𝐀-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐬𝐦𝐚𝐥𝐥 𝐑𝐍𝐀𝐬 𝐢𝐧 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐦𝐲𝐞𝐥𝐨𝐦𝐚: 𝐞𝐥𝐞𝐯𝐚𝐭𝐞𝐝 𝟑′𝐔-𝐭𝐑𝐅𝐒𝐞𝐫𝐓𝐆𝐀 𝐥𝐞𝐚𝐝𝐬 𝐭𝐨 𝐩𝐨𝐨𝐫 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐢𝐬”.
🔗https://t.co/3UbxTifW34

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

🚨 New publication from partner CNRS and colleagues: Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.
Congratulations to the authors on this important contribution. 👏
https://t.co/VjKE9j7tX7

#MultipleMyeloma #CancerResearch #HorizonEU #EUfunding

[Horizon Europe 🇪🇺 @HorizonEU]

How can digital innovation change the way Europe understands and treats cancer?

Join the EU Cancer Mission Conference in Nicosia on 27 April 2026 to explore data-driven projects and strategies to reduce inequalities in cancer care.

🔗https://t.co/KRGEw8mjjf

#MissionCancer

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

🗞️ It's released!
The latest ELMUMY Newsletter is out now, featuring key updates on our mission and latest news!

🔗https://t.co/cqx6dJ5q0X

#MissionCancer #ResearchInnovation #HorizonEurope #Collaboration #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

🎗️ Today is #WorldCancerDay.

We stand united against cancer, raising awareness, supporting research, and working toward accessible care for all. 🙏

#UnitedByUnique #multiplemyeloma #HorizonEU #EUfunding #ELMUMY

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

7th General Assembly Meeting

On 27–28 Jan, our consortium met in Cyprus to review progress and align on the final project phase.
Key advances in clinical data, omics & collaboration as we enter the final year.

#MultipleMyeloma #HorizonEU #ResearchInnovation #Collaboration

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

New paper from our colleagues at @NeuroGeneticsCy in IJMS: "Integrative network analysis of single-cell RNA identifies novel gene regulators in multiple myeloma".
📖 https://t.co/jVZMdAzlzD
👏 Congrats to the CING team!

#MultipleMyeloma #CancerResearch #HorizonEU #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

Proteomic analysis of the isolated populations will follow, led by Dr. Courraud and implemented by 𝐃𝐫. 𝐏𝐚𝐫𝐚𝐬𝐤𝐞𝐯𝐢 𝐊𝐚𝐫𝐨𝐮𝐬𝐢.

#multiplemyeloma #researchinnovation #cancerresearch #collaboration #HorizonEU #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

𝐋𝐚𝐮𝐧𝐜𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐜𝐥𝐨𝐧𝐚𝐥 𝐯𝐬. 𝐧𝐨𝐫𝐦𝐚𝐥 𝐂𝐃𝟏𝟑𝟖⁺ 𝐬𝐩𝐢𝐧-𝐨𝐟𝐟 𝐬𝐭𝐮𝐝𝐲

A new 𝐄𝐋𝐌𝐔𝐌𝐘 spin-off study is beginning, aiming to resolve a key challenge in plasma cell dyscrasias.

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

The first successful sorting session was completed at the Flow Cytometry Facility of 𝐏𝐫𝐨𝐟. 𝐑𝐚𝐧𝐢𝐚 𝐓𝐬𝐢𝐭𝐬𝐢𝐥𝐨𝐧𝐢𝐬’s lab by 𝐃𝐫. 𝐈𝐨𝐚𝐧𝐧𝐢𝐬 𝐊𝐨𝐬𝐭𝐨𝐩𝐨𝐮𝐥𝐨𝐬.

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

𝐏𝐫𝐨𝐟. 𝐄𝐟𝐬𝐭𝐚𝐭𝐡𝐢𝐨𝐬 𝐊𝐚𝐬𝐭𝐫𝐢𝐭𝐢𝐬 and 𝐌𝐫𝐬. 𝐂𝐡𝐫𝐢𝐬𝐭𝐢𝐧𝐞 𝐈𝐯𝐲 𝐋𝐢𝐚𝐜𝐨𝐬 have spent years building a unique biobank and database essential to 𝐄𝐋𝐌𝐔𝐌𝐘’s success.

#multiplemyeloma #cancerresearch #collaboration #HorizonEU #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

The Proteomics Core Facility has reached a major milestone, reflecting the rapid growth of its capabilities and the dedication of its team.

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

The original 𝐄𝐋𝐌𝐔𝐌𝐘 project set ambitious goals; completing such a large batch already exceeds expectations and moves the consortium ahead. This progress was made possible through the long-term vision and commitment of the Alexandra Hospital clinical team.

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

Excited to share our new Proteomics article: “Easy Proteomics Sample Preparation: Technical Repeatability & Workflow Optimization Across 8 Biological Matrices in a New Core Facility Setting". https://t.co/s8xLbgHl1t
#multiplemyeloma #missioncancer #HorizonEU #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

Exciting new study from our partners at NHRF that reveals how DNA damage response and redox imbalance shape apoptosis & sensitivity to genotoxic agents in multiple myeloma cells.
👉 https://t.co/UH2Dyu91oK

Congrats to all!

#MultipleMyeloma #MissionCancer #HorizonEU #EUfunding

[ELMUMY - HORIZON-MISS-2021-CANCER-02-03 @ELMUMYproject]

Dr. Iryna Lishchuk, LL.M., from partner LUH, represented #ELMUMY at the L3S Retreat (7–9 Oct 2025) in Germany.
Iryna presented her poster “IT and Legal Data Sharing Solutions,” showcasing ELMUMY’s goals and insights on IT and legal issues.
#multiplemyeloma #HorizonEU #EUfunding